All In Biotech

Drug Trial Radar · NCT05633602

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 838 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

838

Actual

Start

Mar 14, 2023

Primary completion

Nov 26, 2025

Study completion Mar 15, 2028

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Eli Lilly and Company; Merck Sharp & Dohme LLC
First posted
Dec 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.

Conditions

  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8

Interventions

  • ChemotherapyDrug

    Receive standard of care chemotherapy

  • PembrolizumabBiological

    Given IV

  • RamucirumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: From date of randomization to date of death due to any cause, assessed up to 3 years

Locations

566 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Tower Cancer Research Foundation

    Beverly Hills, California

  • Marshall Cancer Center

    Cameron Park, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Kaiser Permanente Dublin

    Dublin, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Kaiser Permanente - Harbor City

    Harbor City, California

  • City of Hope at Huntington Beach

    Huntington Beach, California

  • City of Hope at Irvine Lennar

    Irvine, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • City of Hope Antelope Valley

    Lancaster, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • City of Hope at Long Beach Elm

    Long Beach, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Kaiser Permanente West Los Angeles

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Kaiser Permanente-Modesto

    Modesto, California

  • City of Hope Newport Beach

    Newport Beach, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Kaiser Permanente-Ontario

    Ontario, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

Showing 40 of 566 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.